In an advance toward conquering covid-19, doctors in Michigan say an antibody drug may sharply cut the chance patients on a ventilator will die.
The problem: The pandemic viral disease is infecting millions, and for those who end up on a ventilator in an ICU, the odds are grim. More than half are dying.
The drug: Doctors at the University of Michigan set out to control the haywire immune reaction that pushes some covid-19 patients into a death spiral. To do it, they gave 78 patients on ventilators the drug tocilizumab, which blocks IL-6, a molecule in the body that sets off a reaction to an infection. (The drug is sold by Roche under the trade name Actemra.)
The result: The doctors say in a preprint that patients who got the drug were 45% less likely to die than those who didn’t. But there’s a big caveat, which is that the doctors knew which patients got the drug and which didn’t. Their picks for the drug-taking group could have been biased— people more likely to improve anyway, for example—so further studies are needed.
Emerging cocktail: In late May, Roche said it would start a trial to combine its IL-6 blocker with remdesivir, an antiviral drug with modest benefits that got emergency approval in the US for treating covid-19. That drug is meant to block the virus from replicating.
By combining the two drugs, doctors may be closing in on a cocktail able to cut the death rate from the virus, a step that would help society return to normal.
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
How AI can help us understand how cells work—and help cure diseases
A virtual cell modeling system, powered by AI, will lead to breakthroughs in our understanding of diseases, argue the cofounders of the Chan Zuckerberg Initiative.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.